A high proportion of diabetic patients experience fungal infections, and pharmaceutical strategies have varying success rates. A new alternative method, hydrophobic interaction, may provide a valuable treatment for these infections diabetic; antifungal; topical therapy; hydrophobic interaction; healing A high proportion of diabetic patients (up to 84%) develop topical inter-digital fungal infections. The most commonly found fungus in these infection is Trichophyton rubrum, which is present in approximately 70% of cases.
Hydrophobic interaction
Hydrophobic interaction occurs when two hydrophobic (water-repellent) surfaces bind to each other in the presence of water or, in the case of wounds, exudate. An important mechanism by which microorganisms, fungi and bacteria adhere to surfaces is the expression of cell surface hydrophobicity. 6 The vast majority of pathogenic microorganisms are hydrophobic. 7 The Sorbact dressing range uses the principles of hydrophobic interaction to bind and eliminate bacteria and fungi from dry to moist wounds. It can be used on all skin types and in fungal infections in skin folds. Microorganisms bind to the dressing's hydrophobic surface and are then inactivated and eliminated. No side-effects or microbial resistance have been reported. 8 Sorbact is manufactured in Sweden by Abigo Medical and distributed in the UK by BSN Medical as Cutimed Sorbact Ribbon.
Few studies have investigated the non-pharmaceutical treatment of fungal skin infections in diabetic patients. This pilot study evaluated the effect of Sorbact in the treatment of interdigital skin infections in people with diabetes mellitus.
Material and methods
Consecutive diabetic patients attending the diabetic foot clinic at the hospital NÄL (Norra Älvsborgs Länssjukhus, Trollhättan, Sweden) who were diagnosed with a topical inter-digital fungal infection were included in the study over a 14-month period. Patients where excluded from the study if the lesion was assessed as non-fungal, the initial culture was negative or they could not follow study protocol. All patients gave informed consent, and ethics committee approval was received.
Intervention
The treatment intervention comprised daily application of Sorbact ribbon gauze (2 x 50cm) for 10 days, in accordance with the manufacturer's recommendations and based on previous in vitro studies. All patients had experienced previous interdigital infections, for which were given topical antifungal pharmaceuticals.
The investigating podiatrist applied the test dressing during the patient's fi rst visit at the outpatient clinic. Patients were given written and oral instructions to wash their feet, dry them carefully, apply the test dressing and change their socks daily.
Assessment
On days 1, 5 and 10, all patients attended the clinic where the infection was assessed by the investigator, by visual inspection. The lesion was evaluated using a four-grade scale:
• Deteriorated • Unchanged (defi ned as <50% reduction in the size of the ulcer)
• Improved (defi ned as >50% reduction in the size of the ulcer) • Healed.
Signifi cant change was considered if the lesion had increased or decreased in size by more than 50%. The wound was defi ned as healed if the skin was intact with no localised reaction.
The same assessments where performed by the patient on days 2, 3, 4, 6, 7, 8 and 9.
The investigator photographed the lesions on days 1, 5 and 10 for an independent evaluation, which was performed by a blinded observer. The blinded observer had no relation to the investigator or patient; the assessment followed the same protocol as outlined above.
Cultures sample were taken before inclusion and on days 1, 5 and 10. Before inclusion, the swab was placed on the infected area for 10 minutes, whereas on days 1, 5 and 10 it was taken from the woundcontact surface of the test dressing. The samples were frozen and sent to the Department of Medical Microbiology, Dermatology and Infection, University of Lund for culture. 8 The investigator and patients assessed their perception of the treatment (defi ned as ease of application), on days 1, 5 and 10. The treatment was graded as:
Results
Twenty patients were recruited into the study, as recommended by the ethics committee. The sample consisted of 14 males and 6 females aged between 26 and 74 years of age. All patients completed the study and no adverse reactions were recorded.
Assessments
Fifteen patients (75%) had improved or healed by day 10. Four patients (20%) remained unchanged and one patient (5%) deteriorated. In the latter patient, the fungal skin reaction improved but the ulceration on the fourth phalanx worsened, perhaps due to mechanical stress from inappropriate footwear ( Table 1) .
Eight patients (44%) found the test dressing 'very easy' to use and seven 39% found it 'easy'. Three patients (17%) found it 'diffi cult'. Of these three patients, one found it diffi cult to dispose of the dressing material and two had diffi culty applying the dressing, due to a stiff back and poor vision in 
Microbiology
The microbiology fi ndings showed a broad variation of fungi present in the treated area:
In a number of cases, no fungi were recorded at day 10. Full details are given in Table 2 . There was a strong correlation between no growth on day 10 and healed or improved lesions. In the cases with growth of fungi on day 10, the lesions where either healed, improved or unchanged.
Photo evaluation
The evaluation of the photographs was complicated in four patients due to the poor quality of the pictures.
On day 10, the blinded assessor considered that two patients (10%) had improved, 10 patients (50%) had healed, seven patients (35%) were unchanged before treatment start, and one patient's wound had deteriorated. (Table 1) .
Discussion
This small, non-comparative, open pilot study showed that the hydrophobic test dressing was an effective treatment for interdigital fungal infections in diabetic patients, with no reported adverse events. According to assessments, 75% of the infections had improved or healed after 10 days of treatment. In 55% of patients, the culture showed no growth of fungi after 10 days of treatment. Furthermore, the investigator and most of the patients found the dressing easy to apply. However, the sample size is too small to determine if the hydrophobic dressing is more effective than other treatments, and a randomised controlled trial (RCT) would be needed to determine this.
There are limited data on the treatment of fungal infections in diabetic patients against which these data can be compared. In a double-blind clinical trial, Schopf et al. randomised 429 patients with tinea pedis (athlete's foot) to topical treatment with either terbinafi ne and lotrimazole. In the subgroup of patients without any protocol violations, 164/173 (95%) given terbinafi ne healed compared with 159/174 (91%) given clotrimazole. A local skin reaction was reported in 4% and 5% in each group respectively. 9 In the present study, no side-effects or resistance was reported for the hydrophobic treatment.
The weakness of this pilot study lies in its open, nonrandomised, non-comparative design and small sam-ple size. A strength of the study is that photographs of the lesions were assessed by a blinded observer, although the focus of four images was too poor to assess reliably. Nevertheless, the results support those of an earlier, unpublished pilot study on interdigital infection, and the current pilot is intended to be a precursor to a RCT with a longer follow-up period.
Conclusion
The results of this pilot study indicate that this hydrophobic treatment may be a valuable alternative treatment for interdigital fungal infections in the diabetic foot. However, more robust evidence, ideally in the form of a RCT, is needed to confi rm this fi nding. ■
